People | June 04, 2026
Dr. Saurabh Lall joins KIMS Hospitals as Chief Operating Officer
Dr. Lall brings extensive experience in healthcare operations, business strategy, and hospital management
Dr. Lall brings extensive experience in healthcare operations, business strategy, and hospital management
The move signals a major expansion in access to next-generation weight-loss therapies
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The approval is supported by results from the Phase 3 SWOG 1826 trial
While overall survival data remain immature, the results pointed to a favourable trend.
Based in the global marketing function, he will be responsible for strengthening the company's visibility among sponsors, partners and industry stakeholders worldwide
Real-time remote collaboration during robotic-assisted cholecystectomy showcases new possibilities for surgical mentoring, education, and knowledge sharing across institutions
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
